TY  - JOUR
AU  - Garcia-Alegria, Eva
AU  - Lafita-Navarro, M Carmen
AU  - Aguado, Rocio
AU  - Garcia-Gutierrez, Lucia
AU  - Sarnataro, Kyle
AU  - Ruiz-Herguido, Cristina
AU  - Martin, Francisco
AU  - Bigas, Anna
AU  - Canelles, Matilde
AU  - Leon, Javier
PY  - 2016
DO  - 10.1016/j.canlet.2016.02.037
UR  - http://hdl.handle.net/10668/9895
T2  - Cancer letters
AB  - Chronic myeloid leukemia (CML) progresses from a chronic to a blastic phase, where the leukemic cells are proliferative and undifferentiated. The CML is nowadays successfully treated with BCR-ABL kinase inhibitors as imatinib and its derivatives. NUMB...
LA  - en
PB  - Elsevier
KW  - Chronic myeloid leukemia
KW  - Imatinib
KW  - NUMB
KW  - Antineoplastic agents
KW  - Cell proliferation
KW  - Drug resistance, neoplasm
KW  - Fusion proteins, bcr-abl
KW  - Gene expression
KW  - Genes, dominant
KW  - HeLa cells
KW  - Humans
KW  - Imatinib mesylate
KW  - K562 cells
KW  - Leukemia, myelogenous, chronic, BCR-ABL positive
KW  - Membrane proteins
KW  - Nerve tissue proteins
KW  - Signal transduction
TI  - NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.
TY  - research article
VL  - 375
ER  -